Medical, Surgical and Cosmetic Dermatologist, David A Bushore, MD, owner of Balcones Dermatology and Aesthetics in Austin, Texas and creator of the Austin Natural Look™ now offers Kybella®.

Kybella® is an FDA approved injectable designed to permanently dissolve fat under the chin, also known as submental fat or double chin. The revolutionary fat dissolving injectable is comprised of deoxycholic acid, a naturally occurring substance in the body, which typically helps break down fats during the digestive process.

When Kybella® is injected under the chin, it breaks down fat molecules located specifically in the submental area, so they can be absorbed by the body’s immune system, ultimately getting rid of chin fat, also known as “the double chin.”

During each treatment, Dr. Bushore uses an evenly spaced grid in order to precisely administer Kybella®, ensuring an even result.

The Kybella® injection process takes about 15-20 minutes. Patients may experience swelling for up to 5-7 days. Generally, patients require 2-4 injections spaced 2 months apart. Results should be permanent as long as body weight remains stable.

Balcones Dermatology - Kybella
Balcones Dermatology - Kybella
Balcones Dermatology - Kybella
Balcones Dermatology - Kybella
Balcones Dermatology - Kybella
KYBELLA® (deoxycholic acid) injection 10 mg/mL Important InformationIndication
: KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

Important Safety Information

KYBELLA® is contraindicated in the presence of infection at the injection sites.
Warnings and Precautions: 
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising: 
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures: 
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Adverse Reactions: 
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.